Department of Musculoskeletal Ageing and Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK.
Department of Orthopedics, Police General Hospital, Bangkok 10330, Thailand.
Mar Drugs. 2023 Jul 13;21(7):399. doi: 10.3390/md21070399.
Sarcopenia, a progressive disease characterized by a decline in muscle strength, quality, and mass, affects aging population worldwide, leading to increased morbidity and mortality. Besides resistance exercise, various nutritional strategies, including omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation, have been sought to prevent this condition. This narrative review summarizes the current evidence on the effect and mechanism of n-3 PUFA on musculoskeletal health. Despite conflicting evidence, n-3 PUFA is suggested to benefit muscle mass and volume, with more evident effects with higher supplementation dose (>2 g/day). n-3 PUFA supplementation likely improves handgrip and quadriceps strength in the elderly. Improved muscle functions, measured by walking speed and time-up-to-go test, are also observed, especially with longer duration of supplementation (>6 months), although the changes are small and unlikely to be clinically meaningful. Lastly, n-3 PUFA supplementation may positively affect muscle protein synthesis response to anabolic stimuli, alleviating age-related anabolic resistance. Proposed mechanisms by which n-3 PUFA supplementation improves muscle health include 1. anti-inflammatory properties, 2. augmented expression of mechanistic target of rapamycin complex 1 (mTORC1) pathway, 3. decreased intracellular protein breakdown, 4. improved mitochondrial biogenesis and function, 5. enhanced amino acid transport, and 6. modulation of neuromuscular junction activity. In conclusion, n-3 PUFAs likely improve musculoskeletal health related to sarcopenia, with suggestive effect on muscle mass, strength, physical performance, and muscle protein synthesis. However, the interpretation of the findings is limited by the small number of participants, heterogeneity of supplementation regimens, and different measuring protocols.
肌肉减少症是一种以肌肉力量、质量和量减少为特征的进行性疾病,影响着全世界的老年人口,导致发病率和死亡率增加。除了抗阻运动外,还寻求了各种营养策略,包括ω-3 多不饱和脂肪酸(n-3 PUFA)补充,以预防这种情况。本叙述性综述总结了 n-3 PUFA 对肌肉骨骼健康影响和作用机制的现有证据。尽管证据相互矛盾,但 n-3 PUFA 被认为有益于肌肉质量和体积,较高的补充剂量(>2 g/天)效果更为明显。n-3 PUFA 补充可能改善老年人的手握力和股四头肌力量。观察到步行速度和起立-行走测试等肌肉功能的改善,尤其是在补充时间更长(>6 个月)的情况下,尽管变化较小,且不太可能具有临床意义。最后,n-3 PUFA 补充可能对肌肉蛋白合成对合成代谢刺激的反应产生积极影响,缓解与年龄相关的合成代谢抵抗。n-3 PUFA 补充改善肌肉健康的机制包括 1. 抗炎特性,2. 机械靶蛋白复合物 1(mTORC1)途径表达增强,3. 细胞内蛋白质分解减少,4. 线粒体生物发生和功能改善,5. 氨基酸转运增强,以及 6. 运动神经元连接活动的调节。总之,n-3 PUFAs 可能改善与肌肉减少症相关的肌肉骨骼健康,对肌肉质量、力量、身体表现和肌肉蛋白合成有提示作用。然而,由于参与者数量少、补充方案的异质性以及不同的测量方案,对这些发现的解释受到限制。